[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364956-105":59,"doc-detail-364956-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","phenotypes-and-cytokines-of-nk-cells-in-triple-negative-breast-cancer-resistant-to-checkpoint-blockade-immunotherapy","Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy","","Neoadjuvant checkpoint blockade immunotherapy (NATI) improves outcomes in triple-negative breast cancer (TNBC), yet residual tumor cells after NATI represent high-risk populations that can evade NK-cell immunosurveillance. Using an 82-protein panel, single-cell membrane proteomics profiled CD56+ (NCAM1+) NK cells from tumor, peri-cancerous tissue, and peripheral blood in 28 TNBC patients with residual cancer burden II/III post-NATI. Unsupervised clustering identified distinct tumor-infiltrating and peri-cancerous NK clusters with divergent activation and suppression programs. Single-cell secreting proteomics with a 32-cytokine panel showed SELL+ TINK clusters exhibited immunosuppressive IL10+ secretion patterns, and lower proportions of these clusters associated with better progression-free survival. Findings were validated in an independent cohort of 15 patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/phenotypes-and-cytokines-of-nk-cells-in-triple-negative-breast-cancer-resistant-to-checkpoint-blockade-immunotherapy/364956/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/phenotypes-and-cytokines-of-nk-cells-in-triple-negative-breast-cancer-resistant-to-checkpoint-blockade-immunotherapy/364956.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address after NATI in TNBC?","Question",{"text":112,"@type":113},"Residual tumor cells that survive NATI are high-risk and often evade immunosurveillance by NK cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were NK-cell phenotypes profiled in this research?",{"text":117,"@type":113},"The study used single-cell membrane proteomics with an 82-protein panel on CD56+ (NCAM1+) NK cells from tumor, peri-cancerous tissue, and peripheral blood.",{"name":119,"@type":110,"acceptedAnswer":120},"Which NK-cell cytokine pattern is linked to survival outcomes?",{"text":121,"@type":113},"SELL+ tumor-infiltrating NK clusters showed immunosuppressive IL10+ secretion patterns, and lower proportions of these IL10+ SELL+ TINK cells were associated with better progression-free survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364956,1790195227,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Wang et al. Breast Cancer Research (2025) 27:51 [https://doi.org/10.1186/s13058-025-02003-y](https://doi.org/10.1186/s13058-025-02003-y)  \nBreast Cancer Research  \nRESEARCH Open Access  \nPhenotypes and cytokines of NK cells in triple- negative breast cancer resistant to checkpoint blockade immunotherapy  \nYoulong Wang 1†, Yongluo Jiang2,3†, Fadian Ding4,5,6,7†, Jun Lu8, Tong Huang9, Guanqing Zhong3,10*, Pengfei Zhu 11, Yue Ma 12, Jin Li 13, Xinjia Wang 14,15, Jiacai Lin 16, Hongjun Zheng 17, Weidong Wang 15, Yiwei Xu 18, Xiajie Lyu 19, Yu Si Niu20, Xin Qi21, Jinjian Li8, Bocen Chen22, Tingting He23, Jiling Zeng2,3 and Yifei Ma4,5,6,7*  \nAbstract  \nNeoadjuvant checkpoint blockade immunotherapy (NATI) significantly prolonged outcomes for triple-negative breast cancer (TNBC) . Residual tumor cells that survive NATI represent high-risk cell populations with metastatic potential and usually evade immunosurveillance by NK cells. Using an 82-protein panel, we here profiled single-cell membrane proteomics of CD56+ (NCAM1+) NK cells from tumor, peri-cancerous tissue, as well as peripheral blood from 28 TNBC patients post-NATI of residual cancer burden II/III. Unsupervised clustering resulted in several distinct clusters: 2 tumor-infiltrating NK (TINK) clusters with divergent functions of immune activation (TNFRSF7+) and suppression (SELL+); 2 immuno-suppressive peri-cancerous clusters; and 1 periphery-specific cluster. Considering the contradiction of the 2 TINK clusters, we further tested cytokine functions of SELL +and TNFRSF7 + TINKs by single-cell secreting proteomics using a 32-cytokine panel. Consistently, SELL + TINK clusters were characterized by immuno-suppressive secretion patterns (IL10+) . A low proportion of SELL + TINK cluster and low proportion of IL10 + secreting SELL + TINK cluster (single-cell secreting proteomics) were both associated with better progressionfree survival time. These findings were validated in an independent cohort of 15 patients during 16-month follow-up. Overall, we identified a distinct immuno-suppressive TINK cell group, featuring IL10 + secreting and SELL expression with a strong relation to poor survival prognosis in TNBC patients post-NATI.  \n†Youlong Wang, Yongluo Jiang and Fadian Ding contributed equally to this work.  \n*Correspondence: Guanqing Zhong [zhonggq@sysucc.org.cn](zhonggq@sysucc.org.cn)[ ](zhonggq@sysucc.org.cn)Yifei Ma [myf61872169@163.com](myf61872169@163.com)  \nFull list of author information is available at the end of the article  \nIntroduction  \nTripple-negative breast cancers (TNBC) lack expression of HER2, ER, and PR, have a high risk of metastasis, and bring about poor survival prognosis, accounting for 10–15% of invasive breast cancers [1]. Neoadjuvant therapy by immune checkpoint inhibitors (NATI) is reported as a preferred regimen for early-phase TNBC due to high probability of achieving better resection rates which can substantially increase pathological complete response (pCR) and prolong survival outcomes [2, 3]. Mechanism of augmented anti-tumor immunity in immune checkpoint inhibition (ICI) relates to progression death-1 (PD1) receptor or ligand (PDL1) blockage and  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use ","cbCaiaPm2Pv2PVtU","https://ap.wps.com/l/cbCaiaPm2Pv2PVtU","pdf",3961029,11,"English","# Abstract\n## Single-cell proteomics of CD56+ NK cells\n## Cytokine profiling and functional testing\n## Clinical association and validation","[{\"question\":\"What problem does the study address after NATI in TNBC?\",\"answer\":\"Residual tumor cells that survive NATI are high-risk and often evade immunosurveillance by NK cells.\"},{\"question\":\"How were NK-cell phenotypes profiled in this research?\",\"answer\":\"The study used single-cell membrane proteomics with an 82-protein panel on CD56+ (NCAM1+) NK cells from tumor, peri-cancerous tissue, and peripheral blood.\"},{\"question\":\"Which NK-cell cytokine pattern is linked to survival outcomes?\",\"answer\":\"SELL+ tumor-infiltrating NK clusters showed immunosuppressive IL10+ secretion patterns, and lower proportions of these IL10+ SELL+ TINK cells were associated with better progression-free survival.\"}]","Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy | PDF",1790159515,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3f9991d0bacd2f9fbd2263b5b3f2da9.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e99a53f18de0d69b5f9c6d1007970fd.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c978326adce82255e170b399ee77c719.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87917923d919e5c0cfff1ab82d69fbec.webp",980,1306]